Isomorphic Labs
Isomorphic Labs raises $600M Series B at $3.5B valuation
Quick Facts
Isomorphic Labs: Series B Funding Round
Isomorphic Labs has successfully raised $600M in Series B funding, reaching a valuation of $3.5B.
Company Overview
AI-powered drug discovery platform applying machine learning to molecular design
Funding Details
The Series B round was led by Alphabet, with participation from Andreessen Horowitz.
Company Information
- Headquarters: London, UK
- Founded: 2021
- Employees: 150+
- Category: Biotech
Investment
Isomorphic Labs plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Alphabet: Verified investor in Series B
- Andreessen Horowitz: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
